COLL Q2 2019 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$75M+2.7% YoY

Gross Profit

$26M35.2% margin

Operating Income

-$5M-6.7% margin

Net Income

-$5M-6.3% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

$15M

Free Cash Flow

$14M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$302M

Total Liabilities

$216M

Stockholders' Equity

$86M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$73M	+2.7%
Gross Profit	$26M	$26M	+0.6%
Operating Income	-$5M	-$7M	+31.3%
Net Income	-$5M	-$13M	+63.9%

Revenue Segments

Nucynta

$49M65%

Xtampza

$26M35%